Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mangaciclanol
- Development stage
- Phase 3
- Lead developer
- GE Healthcare
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Mangaciclanol (GEH200486) is a macrocyclic manganese-based contrast agent (MnBCA) developed by GE Healthcare for use in magnetic resonance imaging (MRI). It is designed to enhance the detection and characterization of lesions in the central nervous system (CNS) and other body tissues by shortening the T1 relaxation time of water protons, thereby increasing signal intensity on T1-weighted images. As a manganese-based agent, it serves as a potential alternative to gadolinium-based contrast agents (GBCAs), aiming to provide high diagnostic efficacy while avoiding the specific safety concerns associated with gadolinium retention in tissues. It is currently being evaluated in Phase 2/3 clinical trials, such as the LUMINA study, to assess its efficacy and safety in adult patients referred for contrast-enhanced MRI.
- Other names
- GEH200486 InjectionGEH-200486 InjectionGEH 200486 Injection
Beyond the preview
Go deeper on mangaciclanol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mangaciclanol.